A pharmaceutical programme can bring an ingredient producer, a development or manufacturing partner, process-equipment suppliers and packaging specialists into the same sourcing trip. That convenience also creates a risk: a polished conversation in one workstream can sound relevant to the whole programme even when the company controls only one part. CPHI & PMEC China 2027 is most useful when every meeting begins with the same product and market case, then follows an evidence path suited to that supplier’s actual responsibility.
The event runs from 16–18 June 2027 at the National Exhibition and Convention Center in Shanghai. Its official scope covers pharmaceutical ingredients, excipients, natural products, biotechnology, contract services and finished dosage, together with pharmaceutical machinery, packaging and drug delivery, laboratory equipment and clean technology. The range supports one connected programme, but it does not make the four supplier types interchangeable.
| Open decision | Meeting counterpart | Evidence to pursue first |
|---|---|---|
| Select an API or excipient source | Material manufacturer and proposed site | Exact grade, specification, analytical package, change and continuity controls |
| Select development or manufacturing support | CDMO/CMO legal entity and operating site | Technical scope, transfer plan, quality responsibilities, capacity and timeline |
| Define a process or packaging line | Equipment builder and service team | User-requirement response, interfaces, acceptance plan, documentation and support |
| Develop primary or secondary packaging | Packaging converter or system supplier | Material structure, compatibility, line fit, artwork/change control and traceability |
Build one product case before splitting the workstreams
Start with a concise programme brief: dosage form, strength or presentation, development stage, target market or markets, intended users where relevant, forecast volume, batch assumptions, launch timing, storage and distribution conditions, critical quality attributes and proposed packaging. State which elements are fixed, which are preferred and which remain open to supplier input.
Add the process context needed for meaningful discussion. For a material, that may include its function, target specification and expected quantity. For a manufacturing service, include the current development package, scale and transfer stage. For equipment, provide the product, process sequence, batch or line capacity, utilities and space constraints. For packaging, identify the dosage form, filling or packing interface, barrier needs, distribution stresses and available stability knowledge.
The same brief should also identify the buyer’s decision gates. A discovery meeting may only establish relevance. A technical review may determine whether samples, a confidentiality agreement or a request for information should follow. A site visit, audit, engineering review or commercial proposal belongs later and needs its own scope. Defining these gates keeps the show from turning into a collection of unrelated brochures and promises.
Follow the material from specification to supply continuity
Ingredient and excipient meetings should begin with the exact material and grade, not a broad catalogue. Record the manufacturer, legal seller, proposed manufacturing site, production route at an appropriate level, specification, analytical methods, compendial position where applicable, packaging, storage, retest or expiry basis and normal batch size. Ask which documents and samples can be supplied for the buyer’s intended use and market.
Technical evidence may include identity and assay controls, impurity knowledge, residual solvents, elemental or microbiological controls where relevant, method information, certificates by batch and stability support. The required package depends on the material, product and destination; the buyer’s authorised quality and regulatory teams must decide whether it is adequate. A supplier’s work for another market is useful background, not automatic acceptance for this programme.
Supply reliability deserves a separate conversation. Clarify stated capacity, typical lead time, raw-material dependencies, alternative lines or sites, inventory policy, business-continuity arrangements and the notice process for changes. Link each sample and document to the named manufacturer, site, grade and revision. Without that identity, a successful laboratory sample may not represent the future commercial supply.
Commercial comparison should use the same grade, packaging, quantity, delivery basis and document scope. Note minimum order, batch constraints, price validity, testing or documentation charges, sample quantities, payment terms and the process for forecasts or reserved capacity. This makes cost visible without allowing a lower quotation to hide a different technical or supply basis.
Define the contract partner’s exact role
Contract development and manufacturing discussions vary widely. One company may provide formulation development, another analytical work, clinical or exhibit batches, technology transfer, commercial production, packaging or several of these services. Map the proposed legal entity, operating site and subcontracted activities before comparing capability.
For each requested stage, identify the buyer’s available package and the partner’s expected output. Discuss process and analytical transfer, material sourcing, method work, scale-up, batch documentation, release responsibilities, deviations, investigations, changes, data ownership, sample retention, intellectual property, confidentiality and record access. A timeline should show buyer inputs, partner activities, review gates and dependencies rather than one unsupported completion date.
Capacity needs context as well. Ask about the proposed equipment train, batch range, scheduling approach, campaign or cleaning considerations where relevant, competing demand and the route from development to commercial scale. If the programme requires specialist containment, environmental conditions, sterile operations or another controlled capability, the project team should define the requirement and verify it through the appropriate technical and quality process.
A follow-up visit becomes valuable once a plausible site and scope exist. It can examine the proposed rooms and equipment, material and personnel flow, documentation practices, warehouse and sample handling, laboratories, utilities, maintenance, data systems and the people who would own the programme. The visit should answer a prepared question set; it is not a substitute for formal qualification, audit, validation or regulatory review.
Turn equipment discussions into an engineering route
Machinery meetings need a user requirement rather than a product brochure. Describe the product characteristics, process step, target capacity or batch range, product-contact materials, cleaning approach, containment or environmental needs where applicable, automation level, data and recipe requirements, upstream and downstream interfaces, available utilities, room constraints and destination conditions.
Ask the supplier to mark compliant points, exceptions, options and assumptions. Record the proposed model and revision, design responsibility, bought-in components, control-system boundary, documentation, drawings, software access, spare parts and service coverage. If several machines form a line, identify who owns integration, line control, guarding, utility coordination and performance at each interface.
Acceptance should be planned before the quotation is treated as comparable. Define design-review outputs, inspection points, factory acceptance, shipment condition, installation, site acceptance, commissioning, training and the evidence required at each stage. Product trials and acceptance criteria must reflect the buyer’s actual process and authorised validation strategy. The equipment supplier can support those activities, but cannot approve the pharmaceutical process on the buyer’s behalf.
Compare commercial scopes item by item: base equipment, change parts, tooling, controls, documentation, packing, freight assumptions, installation, travel, training, commissioning, spare parts, warranty and post-warranty service. Also record exclusions and buyer-supplied items. A clear scope prevents an attractive base price from becoming an incomplete project later.
Treat packaging as part of the product system
Packaging decisions connect product protection, patient or user handling, manufacturing and distribution. Begin with the dosage form, contact conditions, required barrier or protection, pack size, opening or dispensing function, tamper or child-related needs if specified by the project, label and coding space, transport route and intended filling or packing equipment.
For primary packaging, discuss material structure, dimensions and tolerances, extractables or compatibility information where relevant, cleanliness or environmental controls, sterilisation status if required, inspection, traceability and change notification. For secondary packaging and printed components, add artwork workflow, colour or print controls, coding, reconciliation, version control and anti-counterfeit or serialisation interfaces where part of the buyer’s system.
Samples should be identified by specification and revision, then tested through the buyer’s own compatibility, stability, line and transport programme as applicable. Confirm whether commercial material would come from the same site, tooling and process represented by the sample. Packaging approval remains connected to the finished product and market; a component cannot be qualified in isolation merely because its supplier exhibits in a pharmaceutical zone.
Close the show with four evidence-based shortlists
After each meeting, record the supplier type, legal entity, proposed site, exact product or service, current evidence, assumptions, missing documents or samples, technical questions, commercial scope, responsible owner and next decision. Keep separate shortlists for materials, contract services, equipment and packaging, then add an interface register showing where one workstream depends on another.
The first follow-up should be specific: send the product brief, issue a structured information request, request a named sample and document set, arrange a technical call, clarify a quotation or schedule a scoped visit. Suppliers that cannot identify their site, responsibility, proposed solution or next evidence step can be held outside the active shortlist without forcing an immediate final judgment at the show.
Xentra can support exhibitor research, multilingual meetings, scheduling, visit coordination and structured comparison across these workstreams. Final supplier qualification, quality and regulatory decisions, validation, product-safety conclusions, contracting and purchasing approval remain with the buyer’s authorised pharmaceutical, technical, quality, legal and regulatory teams.
Sources
- CPHI & PMEC China official homepage
- Official visitor FAQ and 2027 event details
- Official event zones and visitor overview
- Official pharmaceutical machinery zone
Event information checked on 24 July 2026.